The emergence of somatic RB mutations has been identified in the clinic as a relevant resistance mechanism in breast cancer patients treated with CDKi (37); RB mutation/deletion is a frequent event in sarcomas, with deep deletions detected in a significant proportion of STS in the TCGA sarcoma cohort (16). This evidence concerns the gene RB1 and breast carcinoma.